000			04047nam a22006255i 4500
001			224776
003			IT-RoAPU
005			20221214234803.0
006			m|||||o||d||||||||
007			cr || ||||||||
008			210830t20161996pau fo d z eng d
019			_a(OCoLC)1013941474
020			_a9780812216455 _qprint
020			_a9781512816419 _qPDF
024	7		_a10.9783/9781512816419 _2doi
035			_a(DE-B1597)9781512816419
035			_a(DE-B1597)469609
035			_a(OCoLC)952536854
040			_aDE-B1597 _beng _cDE-B1597 _erda
050		4	_aKF1297.D7 _bG74 1996eb
072		7	_aLAW095000 _2bisacsh
082	0	4	_a346.7303/8 _a347.30638 _220
084			_aonline - DeGruyter
100	1		_aGreen, Michael D. _eautore
245	1	0	_aBendectin and Birth Defects : _bThe Challenges of Mass Toxic Substances Litigation / _cMichael D. Green.
264		1	_aPhiladelphia : _bUniversity of Pennsylvania Press, _c[2016]
264		4	_c©1996
300			_a1 online resource (384 p.)
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0	0	_tFrontmatter -- _tContents -- _tPreface -- _tAcknowledgments -- _tChapter 1. A Birth Defect Child Is Born -- _tChapter 2. Locating Bendectin Within the Mass Toxic Landscape -- _tChapter 3. The Science of Determining Toxic Causation -- _tChapter 4. The Food and Drug Administration -- _tChapter 5. The Wm. S. Merrell Company -- _tChapter 6. A Mother's Quest -- _tChapter 7. The Mekdeci Case -- _tChapter 8. The Unraveling Of Mekdeci -- _tChapter 9. The Proliferation of Bendectin Litigation -- _tChapter 10. Litigating a Multidistrict Case -- _tChapter 11. The Withdrawal of Bendectin -- _tChapter 12. Forging a Mass Toxic Substances Trial -- _tChapter 13. The Settlement and Unsettlement of MDL-486 -- _tChapter 14. The MDL-486 Trial -- _tChapter 15. Aggregative Procedure in Mass Toxic Substances Litigation -- _tChapter 16. The Third Phase of Bendectin Litigation: Oxendine, Richardson, and the Individual Trials -- _tChapter 17. The Legacy of Bendectin for Toxic Causation Law -- _tChapter 18. The Lessons and Non-Lessons of Bendectin Litigation -- _tSelected Bibliography -- _tIndex
506	0		_arestricted access _uhttp://purl.org/coar/access_right/c_16ec _fonline access with authorization _2star
520			_aBenedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation, comparing individual and collective forms of litigation, and illustrating the misunderstandings between scientists and lawyers about the role of science in providing evidence for the legal system.
530			_aIssued also in print.
538			_aMode of access: Internet via World Wide Web.
546			_aIn English.
588	0		_aDescription based on online resource; title from PDF title page (publisher's Web site, viewed 30. Aug 2021)
650		0	_aBendectin (Trademark) _xToxicology.
650		0	_aComplex litigation _zUnited States.
650		0	_aProducts liability _xDrugs _zUnited States.
650		0	_aToxic torts _zUnited States.
650		7	_aLAW / Malpractice. _2bisacsh
653			_aCaregiving.
653			_aHealth.
653			_aHuman Rights.
653			_aLaw.
653			_aMedicine.
850			_aIT-RoAPU
856	4	0	_uhttps://doi.org/10.9783/9781512816419
856	4	0	_uhttps://www.degruyter.com/isbn/9781512816419
856	4	2	_3Cover _uhttps://www.degruyter.com/cover/covers/9781512816419.jpg
942			_cEB
999			_c224776 _d224776